EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study

Mégane Tanguay, Jean Roy, Jiandong Su, Engin Gul, Donna Reece, Christopher P Venner, Darrell White, Michael P Chu, Victor H Jimenez-Zepada, Kevin Song, Arleigh Mccurdy, Hira Mian und 9 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.70332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Mégane Tanguay und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institut universitaire d'hémato-oncologie et de thérapie cellulaire, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Databases, Factual. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Université de Montréal Maryse and William Brock Chair in applied research into stem cell transplantation (J.R. holder), Myeloma Canada Aldo Del Col grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature.

Methods

We explored disease characteristics, treatments, and outcomes following modern therapies of young MM patients using the Canadian Myeloma Research Group (CMRG) database. We included 493 patients ≤ 50 years old diagnosed with MM or plasma cell leukemia without concurrent amyloidosis or POEMS syndrome from January 1, 2010, to July 1, 2022.

Results

The median age was 46 years old (range: 25.6–50). Most patients fell into the R‐ISS II category (72.7%), and 24.1% had high‐risk cytogenetics. The majority of patients (89.9%) received a proteasome inhibitor‐based first‐line treatment, 92.1% received a stem cell transplant, and 65.6% had maintenance therapy post–autologous stem cell transplant (ASCT). Median follow‐up from initial treatment to patients' last follow‐up was 48.5 (range: 0–155) months. Median progression‐free survival (PFS) was 45.0 months (95% CI: 40.2–50.0). Maintenance therapy post‐ASCT improved median PFS to 52.3 months (95% CI: 43.1–68.2), compared to 23.6 months (95% CI: 20.0–34.8) without maintenance [ p < 0.001].

Conclusion

Although the overall survival has not yet been reached in this young population, our reported median PFS of only 45 months highlights the urgent need to develop innovative treatments to induce more profound and durable responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaDatabases, FactualHumansMaleAdultMiddle AgedFemaleCanadaTransplantation, AutologousHematopoietic Stem Cell TransplantationTreatment OutcomeProgression-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsProteasome InhibitorsStem Cell Transplantation

Stichwörter der Autor:innen

chemotherapyclinical observationsepidemiologymultiple myelomaregistriessurvival

Substanzen

Proteasome Inhibitors

Autor:innen und Institutionen

  • Institut universitaire d'hémato-oncologie et de thérapie cellulaire, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada.
  • Université de Montréal, Montréal, Québec, Canada.
  • Canadian Myeloma Research Group, Vaughan, Ontario, Canada.
  • Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • BC Cancer - Vancouver Centre, University of British Columbia, Vancouver, British Columbia, Canada.
  • Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada.

Förderung

  • Université de Montréal Maryse and William Brock Chair in applied research into stem cell transplantation (J.R. holder)
  • Myeloma Canada Aldo Del Col grant

Zitieren

APA

Tanguay, M., Roy, J., Su, J., Gul, E., Reece, D., Venner, C. P., White, D., Chu, M. P., Jimenez-Zepada, V. H., Song, K., Mccurdy, A., Mian, H., Sebag, M., Bergstrom, D., Stakiw, J., Reiman, A., Kotb, R., Aslam, M., Kaedbey, R., …, & LeBlanc, R. (2024). Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study. Cancer Medicine. https://doi.org/10.1002/cam4.70332

Vancouver

Tanguay M, Roy J, Su J, Gul E, Reece D, Venner CP, et al. Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study. Cancer Medicine. 2024. doi:10.1002/cam4.70332

BibTeX
@article{Tanguay2024,
  author = {Tanguay, Mégane and Roy, Jean and Su, Jiandong and Gul, Engin and Reece, Donna and Venner, Christopher P and White, Darrell and Chu, Michael P and Jimenez-Zepada, Victor H and Song, Kevin and Mccurdy, Arleigh and Mian, Hira and Sebag, Michael and Bergstrom, Debra and Stakiw, Julie and Reiman, Anthony and Kotb, Rami and Aslam, Muhammad and Kaedbey, Rayan and Louzada, Martha and LeBlanc, Richard},
  title = {Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70332}
}
Kostenlos starten →